Navigation Links
New method enables design, production of extremely novel drugs
Date:1/23/2008

BUFFALO, N.Y. -- A new chemical synthesis method based on a catalyst worth many times the price of gold and providing a far more efficient and economical method than traditional ones for designing and manufacturing extremely novel pharmaceutical compounds is described by its University at Buffalo developers in a review article in the current issue of Nature.

The chemistry, the basis of a new biotech startup company called Dirhodium Technologies, LLC in Buffalo, has the potential to improve dramatically the design and production of new drugs based on small molecule organic compounds, which comprise the great majority of new drug applications.

If you tend to make things by methods that have been around for 100 years, theres a decent chance that youll make something thats already known or is very close to something that is, said Huw M.L. Davies, Ph.D., UB Distinguished Professor in the Department of Chemistry and lead author on the Nature paper. But if you use an entirely new strategy like the one we developed, virtually every reaction you run will result in a new structural entity. Thats critical to drug development.

The chemical strategy Davies developed depends on the use of proprietary catalysts his company manufactures.

Minute amounts of the rhodium-based catalyst can have a major impact, he explained, with 1 gram capable of producing 10 kilograms of a pharmaceutical product.

So its like a bit of golden dust to get everything going, said Davies, a researcher at UBs New York State Center of Excellence in Bioinformatics and Life Sciences and president and chief executive officer of Dirhodium Technologies.

As rhodium metal costs 10 times the price of gold, the catalyst is a high-value material, he said.

Available through chemical supply companies, the reagents are being used by pharmaceutical scientists in both industry and academia.

Already, one major pharmaceutical company is using the reagents to synthesize a compound now in clinical trials.

Demand for our catalysts has gone from gram to kilogram quantities, from fractions of an ounce to multiple pounds, said Davies.

So far, the new synthesis strategy has generated compounds that have potential activity against a broad range of disease states, from cancer to central nervous system disorders, such as depression, to inflammatory and microbial diseases and medications for treating cocaine addiction.

This method is like an enabling technology, making available new targets and materials that previously were out of range, said Davies.

Its ability to result in never-before-seen chemical structures is making Davies collaborations with scientists in partner institutions on the Buffalo Niagara Medical Campus especially fruitful.

Were using this as a platform for drug discovery, collaborating through the Center of Excellence with biologists at UB, Roswell Park and Hauptman Woodward Medical Research Institute, said Davies.

Davies company is one of 10 life sciences spinoffs based in the Center of Excellence, which has the dual mission of promoting life sciences research while facilitating economic development in Upstate New York.

In addition to helping drug companies design novel leads for new products, the new chemistry also allows pharmaceutical companies to synthesize efficiently and economically large quantities of novel compounds.

Through catalysis, the chemical synthesis method the UB researchers developed allows for highly unusual functionalizations of carbon-hydrogen bonds, Davies explained.

The method allows you to transform a molecule from a simple structure to a much more elaborate, drug-like material, he said, so it goes from a cheap building block to a potential drug-like candidate. Without a catalyst, it wont happen.

A major advantage of Davies chemical strategy is that the resulting compounds are produced selectively as single mirror images.

Pharmaceutical companies prefer to develop new chiral drugs (chiral meaning handed) as a single isomer because opposite mirror images can have different biological effects and may be harmful.

A small amount of our catalyst can be used to generate large amounts of the active mirror image of the pharmaceutical ingredient, Davies said.


'/>"/>

Contact: Ellen Goldbaum
goldbaum@buffalo.edu
716-645-5000 x1415
University at Buffalo
Source:Eurekalert

Related medicine news :

1. Stanford study highlights cost-effective method of lowering heart disease risks
2. Different method of evaluating the urinary tract system reduces radiation dose
3. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
4. A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
5. Researcher developing new method for hearing loss assessment
6. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
7. GPS-like technology helps pinpoint best methods for moving injured players
8. New Seminar Series from Activator Methods Teaches Doctors a Unique Approach to Improving Nations Chiropractic Care: Focus on the Patients
9. Less invasive lymph node biopsy method could spare thousands unnecessary operations
10. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
11. Manchester researchers announce new methods of beating breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology: